WallStSmart

Sanofi ADR (SNY)vsSouthern Company (SO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 58% more annual revenue ($46.72B vs $29.55B). SNY leads profitability with a 16.7% profit margin vs 14.7%. SO appears more attractively valued with a PEG of 2.67. SO earns a higher WallStSmart Score of 54/100 (C-).

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0

SO

Buy

54

out of 100

Grade: C-

Growth: 6.0Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued
SOSignificantly Overvalued (-254.9%)

Margin of Safety

-254.9%

Fair Value

$26.66

Current Price

$94.61

$67.95 premium

UndervaluedFair: $26.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

SO2 strengths · Avg: 8.5/10
Market CapQuality
$105.91B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

SO3 concerns · Avg: 2.0/10
PEG RatioValuation
2.672/10

Expensive relative to growth rate

EPS GrowthGrowth
-22.1%2/10

Earnings declined 22.1%

Free Cash FlowQuality
$-1.86B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bull Case : SO

The strongest argument for SO centers on Market Cap, Price/Book. Revenue growth of 10.1% demonstrates continued momentum.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Bear Case : SO

The primary concerns for SO are PEG Ratio, EPS Growth, Free Cash Flow.

Key Dynamics to Monitor

SNY profiles as a mature stock while SO is a value play — different risk/reward profiles.

SO carries more volatility with a beta of 0.41 — expect wider price swings.

SO is growing revenue faster at 10.1% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

SO scores higher overall (54/100 vs 49/100) and 10.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Southern Company

UTILITIES · UTILITIES - REGULATED ELECTRIC · USA

Southern Company is an American gas and electric utility holding company based in the southern United States. It is headquartered in Atlanta, Georgia, with executive offices also located in Birmingham, Alabama.

Want to dig deeper into these stocks?